UBE2L3 Antibody

What is UBE2L3 and why is it important in research?

UBE2L3 (also known as UbcH7) is an E2 ubiquitin-conjugating enzyme that functions specifically with HECT and RING-in-between-RING (RBR) E3 ligases, including HOIL-1 and HOIP components of the linear ubiquitin chain assembly complex (LUBAC). UBE2L3 is particularly significant in research because:

• It is the preferred E2 conjugating enzyme for LUBAC in vivo

• It is essential for LUBAC-mediated activation of NF-κB signaling

• Genetic variants in UBE2L3 are strongly associated with multiple autoimmune diseases

• It plays a regulatory role in B cell differentiation and proliferation

Understanding UBE2L3 function through antibody-based detection provides critical insights into ubiquitination pathways that regulate inflammation, immunity, and cell survival.

What are the common applications of UBE2L3 antibodies in research?

UBE2L3 antibodies are valuable tools in multiple research applications:

• Western blotting to quantify UBE2L3 protein expression levels

• Immunoprecipitation to study protein-protein interactions with LUBAC components

• Immunohistochemistry to examine tissue distribution patterns

• Flow cytometry to measure UBE2L3 levels in specific immune cell populations

• Co-immunoprecipitation to validate interaction partners

These applications enable researchers to investigate UBE2L3's role in ubiquitination pathways, NF-κB signaling, and autoimmune disease mechanisms.

How do I validate the specificity of UBE2L3 antibodies for my experiments?

Validating antibody specificity is critical for reliable results. For UBE2L3 antibodies, follow these methodological approaches:

• Positive controls: Use cell lines known to express UBE2L3 (e.g., lymphoblastoid cell lines)

• Negative controls: Include samples with UBE2L3 knockdown by siRNA

• Peptide competition: Pre-incubate antibody with excess UBE2L3 peptide to confirm binding specificity

• Cross-reactivity testing: Test antibody against related E2 enzymes like UBE2D3 (UbcH5C)

• Multiple antibody validation: Compare results using antibodies targeting different UBE2L3 epitopes

These validation steps ensure that experimental findings genuinely reflect UBE2L3 biology rather than non-specific antibody interactions.

• Advanced Research Questions About UBE2L3 Antibodies

How can I optimize detection of linear ubiquitination mediated by UBE2L3 in experimental systems?

Detection of linear ubiquitination requires specialized methodological approaches:

• Use antibodies specifically recognizing linear ubiquitin chains (anti-M1-Ub)

• Enrich ubiquitinated proteins using tandem ubiquitin binding entities (TUBEs)

• Employ a two-step immunoprecipitation approach:

  • First IP for the target protein (e.g., NEMO)

  • Second IP with linear ubiquitin-specific antibodies

• Include appropriate controls:

  • Catalytically inactive UBE2L3(C86) mutant

  • UBE2L3 knockdown cells

  • Stimulation with TNFα to induce linear ubiquitination

Research has demonstrated that UBE2L3 is essential for linear ubiquitination of NEMO both in vitro and in vivo. When UBE2L3 was silenced with siRNA, TNFα-induced linear ubiquitination of endogenous NEMO was significantly decreased, confirming UBE2L3's critical role in this process .

How does UBE2L3 expression differ across immune cell populations, and what antibody-based methods best capture these differences?

UBE2L3 shows remarkable cell-type specific expression patterns that can be detected using flow cytometry with intracellular UBE2L3 antibody staining:

For optimal detection:

• Use fresh samples when possible

• Include appropriate isotype controls

• Standardize fixation and permeabilization protocols

• Use multiparameter flow cytometry to simultaneously identify cell subsets and UBE2L3 expression

What are the methodological considerations when studying how UBE2L3 genetic variants affect protein expression and function?

When investigating the impact of UBE2L3 genetic variants (particularly rs140490):

• Genotype selection:

  • Include subjects with homozygous risk, heterozygous, and homozygous non-risk genotypes

  • Match subjects for age, sex, and ethnicity

• Cell type considerations:

  • UBE2L3 genotype effects are strongest in B cells and monocytes

  • Effects are minimal in CD4+ T cells

  • Cell-specific protocols may be needed

• Functional assays:

  • Measure NF-κB activation using nuclear translocation assays

  • Assess response to stimuli (CD40L for B cells, TNF for monocytes)

  • Correlate UBE2L3 levels with cellular phenotypes

• Protein quantification methods:

  • Western blotting with densitometry

  • Flow cytometry for single-cell analysis

  • Standardize against housekeeping proteins

Studies have confirmed that rs140490 risk allele increases UBE2L3 protein levels in CD19+ B cells (p = 0.0094) but does not significantly alter levels in CD4+ T cells, highlighting the importance of cell-type specific analysis .

• Experimental Design Questions for UBE2L3 Antibody Applications

How should experiments be designed to assess the role of UBE2L3 in LUBAC-mediated NF-κB activation?

A comprehensive experimental design to study UBE2L3's role in NF-κB activation should include:

• Cellular models:

  • Primary human B cells and monocytes from genotyped individuals

  • Cell lines with UBE2L3 knockdown, knockout, or overexpression

• Stimulation conditions:

  • TNFα (10 ng/ml) for monocytes

  • CD40L for B cells

  • Time course analysis (0, 5, 15, 30, 60 minutes)

• Readouts:

  • NF-κB nuclear translocation assay

  • Phospho-IκBα Western blot

  • NF-κB reporter assays

  • qPCR for NF-κB target genes

• Controls:

  • Catalytically inactive UBE2L3(C86) mutant

  • UBE2D3 (does not activate NF-κB)

  • Unstimulated cells

Research has shown that the UBE2L3 risk allele correlates with increased basal NF-κB activation in unstimulated B cells and monocytes and regulates the sensitivity of NF-κB to CD40 stimulation in B cells and TNF stimulation in monocytes .

What are the best approaches to studying UBE2L3's role in autoimmune disease pathogenesis using antibody-based methods?

To investigate UBE2L3's contribution to autoimmune disease:

• Patient cohort selection:

  • Stratify by UBE2L3 genotype (rs140490)

  • Include multiple autoimmune conditions (SLE, RA, Crohn's, etc.)

  • Match for disease duration and activity

• Cell population analysis:

  • Use multiparameter flow cytometry with UBE2L3 antibodies

  • Focus on plasmablasts and plasma cells

  • Correlate with disease activity markers

• Functional assessment:

  • Measure ex vivo NF-κB activation in patient cells

  • Assess B cell differentiation and survival

  • Examine cytokine production

• Integration with clinical data:

  • Correlate UBE2L3 expression with disease activity scores

  • Analyze treatment responses

  • Track longitudinal changes

Research has demonstrated that UBE2L3 risk alleles are strongly correlated with increased plasmablast and plasma cell numbers specifically in SLE-affected individuals (p < 0.001), but not in healthy individuals, suggesting disease-specific effects .

How can we distinguish between UBE2L3 and other similar E2 enzymes in experimental systems?

Differentiating UBE2L3 from related E2 enzymes requires specific methodological approaches:

• Antibody selection:

  • Choose antibodies validated for specificity against other E2 enzymes

  • Test for cross-reactivity with purified proteins

• Functional discrimination:

  • UBE2L3 specifically works with HECT and RBR E3 ligases

  • UBE2D3 (UbcH5C) cannot substitute for UBE2L3 in NF-κB reporter assays

  • Only UBE2L3 forms stable complexes with HOIL-1L by co-IP

• Biochemical analysis:

  • In vitro ubiquitination assays with purified components

  • Comparison of catalytic activities and chain type specificities

  • Assessment of E3 ligase interaction patterns

Studies have shown that while the highly homologous E2 enzyme UBE2D3 can assemble linear ubiquitin chains in vitro, it fails to interact with LUBAC components by co-immunoprecipitation and does not trigger NF-κB reporter activity, unlike UBE2L3 .

• Research Applications in Disease Contexts

How can UBE2L3 antibodies be used to study the relationship between UBE2L3 expression and autoimmune disease risk?

UBE2L3 antibodies enable several approaches to investigate the link between UBE2L3 and autoimmune disease:

• Genotype-phenotype correlation:

  • Measure UBE2L3 protein levels in cells from individuals with known risk genotypes

  • Compare expression across different immune cell subsets

  • Correlate with disease susceptibility

• Flow cytometric analysis:

  • Quantify UBE2L3 in plasmablasts and plasma cells from patients

  • Compare levels between different autoimmune conditions

  • Correlate with disease-specific biomarkers

• Tissue analysis:

  • Immunohistochemistry of affected tissues

  • Co-staining with markers of inflammation

  • Assessment of UBE2L3 in infiltrating immune cells

• Longitudinal studies:

  • Monitor UBE2L3 levels during disease flares and remission

  • Assess changes following therapeutic interventions

Studies have shown that the rs140490 risk allele was strongly correlated with increased UBE2L3 expression in EBV-transformed lymphoblastoid cell lines (p = 6.06 × 10^-25), primary human B cells (p = 1.28 × 10^-9), and monocytes (p = 2.54 × 10^-27) .

What methodological challenges exist when using UBE2L3 antibodies to investigate its role in diverse cellular processes?

Researchers face several methodological challenges when studying UBE2L3:

• Specificity issues:

  • Cross-reactivity with homologous E2 enzymes

  • Need for careful validation in each experimental system

  • Requirement for multiple antibody clones targeting different epitopes

• Detecting dynamic changes:

  • UBE2L3 involvement in ubiquitination is rapid and transient

  • Need for synchronized cell populations

  • Optimization of lysis conditions to preserve interactions

• Cell type heterogeneity:

  • Variable expression across cell populations

  • Requirement for cell sorting or single-cell analysis

  • Different optimal detection methods for different cell types

• Context-dependent functions:

  • UBE2L3 may interact with different E3 ligases in different contexts

  • Role in mitophagy versus immune signaling may require different approaches

  • Need to consider cellular activation state

To address these challenges, researchers should employ multiple complementary techniques and include appropriate controls for each experimental system.

How can researchers analyze the impact of UBE2L3 on plasmablast and plasma cell development in autoimmune conditions?

To study UBE2L3's influence on plasma cell development:

• Experimental approaches:

  • Flow cytometric quantification of plasmablasts and plasma cells

  • Cell sorting followed by Western blot for UBE2L3

  • In vitro B cell differentiation assays with UBE2L3 modulation

• Patient stratification:

  • Group by UBE2L3 genotype (rs140490)

  • Match for disease activity and treatment status

  • Include both healthy controls and disease subjects

• Analytical parameters:

  • Quantify both UBE2L3 protein levels and cell numbers

  • Measure proliferation markers (Ki-67)

  • Assess activation markers (CD95)

• Correlations with disease metrics:

  • Analyze relationship with serum autoantibody levels

  • Compare with complement levels (C3, C4)

  • Assess disease activity scores (e.g., SLEDAI)

Research has shown that UBE2L3 protein levels are 3-4 fold higher in plasmablasts and plasma cells compared to other B cell subsets (p < 0.0001), suggesting a critical role in these populations. Furthermore, UBE2L3 levels were significantly elevated in plasma cells from SLE patients compared to healthy controls (p = 0.012) .

• Technical Considerations for Advanced Applications

What are the optimal conditions for detecting UBE2L3-mediated linear ubiquitination events in cell signaling studies?

To effectively detect UBE2L3-mediated linear ubiquitination:

• Sample preparation:

  • Rapid lysis under denaturing conditions (1% SDS)

  • Include deubiquitinase inhibitors (N-ethylmaleimide, PR-619)

  • Use phosphatase inhibitors to preserve signaling intermediates

• Stimulation parameters:

  • TNFα at 10 ng/ml for 5-15 minutes for optimal linear ubiquitination

  • Include time course to capture transient modifications

  • Compare wild-type and UBE2L3-depleted cells

• Detection strategy:

  • Sequential immunoprecipitation:

    • First IP for target protein (e.g., NEMO)

    • Second IP with linear ubiquitin-specific antibodies

  • Use linkage-specific antibodies that recognize linear (M1) ubiquitin chains

  • Include controls with catalytically inactive UBE2L3(C86)

Experiments have demonstrated that linear ubiquitin was detected in NEMO immunoprecipitates when wild-type UBE2L3 was present with LUBAC components, but not when catalytically inactive UBE2L3 was used or when LUBAC components were absent .

How can researchers reconcile contradictory data when studying UBE2L3 across different cell types and disease models?

When faced with contradictory results:

• Consider cell type specificity:

  • UBE2L3 genotype affects expression more strongly in B cells and monocytes than T cells

  • Different cell types may have different thresholds for UBE2L3-dependent activation

  • Expression patterns vary dramatically across immune cell subsets

• Examine technical variables:

  • Different antibody clones may recognize different epitopes or conformations

  • Lysis conditions may affect detection of certain interactions

  • Fixation methods for flow cytometry can impact epitope accessibility

• Account for disease heterogeneity:

  • UBE2L3 risk alleles may have disease-specific effects

  • Disease activity and treatment status may confound results

  • Genetic background may contain modifying factors

• Integration approaches:

  • Employ multiple detection methods

  • Use both cell lines and primary cells

  • Correlate in vitro findings with ex vivo and in vivo data

For example, while rs140490 genotype significantly affected UBE2L3 protein levels in CD19+ B cells (p = 0.0094), the effect was not significant in CD4+ T cells, highlighting the importance of cell-specific analysis .

What are the best protocols for analyzing UBE2L3's interaction with different E3 ligase complexes?

To effectively study UBE2L3's interactions with E3 ligases:

• Co-immunoprecipitation approaches:

  • Use mild lysis conditions (1% NP-40 or Triton X-100)

  • Include protease and deubiquitinase inhibitors

  • Perform reciprocal IPs (pull down UBE2L3 or E3 ligase)

• In vitro binding assays:

  • Express and purify recombinant proteins

  • Perform direct binding assays with purified components

  • Use GST pull-down or His-tag pull-down assays

• Proximity-based methods:

  • BioID or TurboID for detecting transient interactions

  • Proximity ligation assay for in situ detection

  • FRET-based approaches for live-cell analysis

• Functional validation:

  • In vitro ubiquitination assays with purified components

  • Cell-based ubiquitination assays following manipulation of UBE2L3

  • Readouts specific to the E3 ligase pathway (e.g., NF-κB for LUBAC)

Research has shown that endogenous HOIL-1L interacts with endogenous UBE2L3 in vivo, and these associations remain stable following TNFα stimulation. Direct interactions between UBE2L3 and HOIL-1L have been confirmed using bacterially expressed proteins .